Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Umeclidinium / vilanterol (as trifenatate) (Anoro® Ellipta®) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). |
|||
|
|||
Medicine details |
|||
| Medicine name | umeclidinium / vilanterol (as trifenatate) (Anoro® Ellipta®) | ||
| Formulation | 55 micrograms / 22 micrograms inhalation powder | ||
| Reference number | 1038 | ||
| Indication | Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease |
||
| Company | GlaxoSmithKline | ||
| BNF chapter | Respiratory system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 0215 | ||
| NMG meeting date | 07/01/2015 | ||
| AWMSG meeting date | 11/02/2015 | ||
| Ratification by Welsh Government | 10/03/2015 | ||
| Date of issue | 11/03/2015 | ||
| Date of last review | 20/12/2017 | ||